Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Nivolumab
100%
Brentuximab Vedotin
100%
Refractory Hodgkin Lymphoma
100%
Relapsed/refractory Hodgkin Lymphoma
100%
Relapsed/refractory
100%
Infusion Reaction
25%
Autologous Stem Cell Transplantation (auto-SCT)
25%
Inflammatory Cytokines
12%
4-cycle
12%
Adverse Events
12%
Regulatory T Cells
12%
Conventional Chemotherapy
12%
Serum Levels
12%
Treatment Response
12%
First Cycle
12%
Combination Treatment
12%
Thymus
12%
Salvage Therapy
12%
T Cell Subsets
12%
Peripheral T Cells
12%
Systemic Steroids
12%
Objective Response Rate
12%
Salvage Regimen
12%
First Dose
12%
Complete Response Rate
12%
Classical Hodgkin Lymphoma
12%
Activation-regulated Chemokine
12%
Lugano Classification
12%
Reduced Serum
12%
Well Tolerated
12%
Phase 1/2 Study
12%
Proinflammatory Chemokines
12%
Immune-related Adverse Events (IrAEs)
12%
Medicine and Dentistry
Hodgkin's Lymphoma
100%
Nivolumab
100%
Brentuximab Vedotin
100%
Infusion
25%
Autologous Stem Cell Transplantation
25%
Infusion Related Reaction
25%
Cytokine
12%
T Cell Subset
12%
Regulatory T Cell
12%
Chemokine
12%
Treatment Response
12%
Salvage Therapy
12%
Steroids
12%
Immune-Related Adverse Events
12%
Classical Hodgkin Lymphoma
12%
Chemotherapy
12%
Thymus and Activation Regulated Chemokine
12%